SCHEDULE: Affinity Asset Advisors Discloses 5.5% Stake in Avalo Therapeutics

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 1,340,840 shares, representing 5.5% of Avalo Therapeutics, Inc.'s common stock as of March 31, 2026.

Summary

• Affinity Asset Advisors, LLC, acting as the investment manager for Affinity Healthcare Fund, LP, and its managing member Michael Cho, have disclosed their beneficial ownership of Avalo Therapeutics, Inc. common stock.
• As of March 31, 2026, the reporting persons collectively beneficially own 1,340,840 shares of common stock.
• This ownership stake represents approximately 5.5% of the total outstanding common stock of Avalo Therapeutics, Inc.
• The percentage is based on 24,502,449 shares outstanding as of March 26, 2026, as per the Issuer's Definitive Proxy Statement filed on April 10, 2026.
• Affinity Asset Advisors, LLC holds sole voting and dispositive power over these shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but provides no operational or financial performance data, making it purely informational regarding investor positioning.

Positives

• Significant ownership stake of 5.5% indicates a notable investor interest in Avalo Therapeutics.
• The reporting persons have sole voting and dispositive power, suggesting direct control over their investment decisions.
• The certification confirms ordinary course of business holdings, which is standard for institutional investors.

Negatives

• No specific financial performance data or operational updates are provided in this Schedule 13G filing.

Risks

• The filing does not explicitly mention any risks. However, as a Schedule 13G, it primarily reports ownership stakes, not operational risks of the company.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The filing includes a certification stating: 'By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.'

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment funds accumulating significant stakes in publicly traded companies. This filing indicates Affinity Asset Advisors' strategic interest in Avalo Therapeutics, potentially as a long-term investment or a precursor to further engagement.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor may influence market perception and potentially attract further investor interest or scrutiny.
• Management: The filing confirms the reporting persons' intent to hold shares in the ordinary course of business, not to influence control, which is a standard assurance.

Next Steps

• Monitor future filings from Affinity Asset Advisors and Avalo Therapeutics for any changes in ownership or strategic developments.

Key Dates

Keywords

Avalo Therapeutics, Schedule 13G, Affinity Asset Advisors, Michael Cho, Beneficial Ownership, Common Stock, SEC Filing, Investment Management